(:FIXX)

Mar 18, 2024 04:30 pm ET
Homology Medicines Declares Distribution to Common Stockholders
Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding...
Mar 01, 2024 11:26 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, SCTL, FIXX, GRPH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Everi Holdings Inc. (NYSE: EVRI)’s...
Mar 01, 2024 10:48 am ET
Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn...
Feb 27, 2024 03:29 pm ET
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Jan 27, 2024 12:10 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:        Eagle Bulk Shipping Inc. (NYSE:...
Jan 26, 2024 10:35 pm ET
HOMOLOGY MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Jan 03, 2024 04:08 pm ET
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“Nasdaq Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the...
Nov 30, 2023 01:19 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SIX, FIXX, ROVR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Six Flags Entertainment Corporation...
Nov 22, 2023 07:10 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, PATI, FIXX, FRLN
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Spirit Realty Capital, Inc. (NYSE:...
Nov 22, 2023 05:20 pm ET
SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of PFIN, SRT, FIXX, SMMF to Take Action
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Nov 21, 2023 01:02 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, SRC, PATI, FIXX
NEW YORK, Nov. 21, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 20, 2023 07:29 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - NGAB, PFIN, SRT, FIXX
NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Nov 18, 2023 09:34 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, PATI, FIXX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Spirit Realty Capital, Inc. (NYSE:...
Nov 17, 2023 08:00 pm ET
SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of NGAB, FIXX, CNSL, SRT to Take Action
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Nov 17, 2023 06:15 pm ET
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Nov 16, 2023 12:55 pm ET
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Homology Medicines, Inc. (NASDAQ: FIXX) and Q32 Bio Inc. is fair to Homology shareholders. Upon completion of the proposed transaction, Homology shareholders are expected to own approximately 25% of the combined company.
Nov 16, 2023 07:05 am ET
Q32 Bio and Homology Medicines Announce Merger Agreement
Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the...
Nov 16, 2023 06:05 am ET
Q32 Bio and Homology Medicines Announce Merger Agreement
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders--
Nov 14, 2023 04:33 pm ET
Homology Medicines Reports Third Quarter 2023 Financial Results
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates. Homology recently shared a summary of safety and efficacy data on the first dose cohort of...
Aug 14, 2023 04:05 pm ET
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates. “We recently shared the encouraging initial data from the first dose level of the pheEDIT...
Jul 27, 2023 04:05 pm ET
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value....
Jul 27, 2023 04:01 pm ET
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today encouraging initial clinical data from the first dose cohort in the pheEDIT Phase 1, dose-escalation trial evaluating gene editing candidate HMI-103 in adults...
May 16, 2023 08:00 am ET
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meetin
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today six presentations supporting its gene editing, gene therapy and GTx-mAb programs at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting,...
May 11, 2023 04:05 pm ET
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments. “We look forward to announcing the first gene editing data...
May 03, 2023 07:30 am ET
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASG
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH)....
Mar 15, 2023 04:01 pm ET
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 pheEDIT gene...
Mar 09, 2023 04:05 pm ET
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments. “We entered 2023 with strong momentum...
Mar 09, 2023 08:00 am ET
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development...
Mar 06, 2023 09:30 am ET
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. and Encourages Long-Term FIXX Stockholders to Contact the Firm
Investor protection law firm Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of the Company’s long-term stockholders. Recently an amended securities fraud complaint...
Mar 02, 2023 07:30 am ET
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare...
Feb 22, 2023 04:01 pm ET
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annua
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that supports the targeted, prophylactic immunosuppression regimen in the ongoing pheEDIT gene editing clinical trial in...
Jan 04, 2023 04:01 pm ET
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today enrollment and site status updates from the pheEDIT Phase 1 gene editing trial with HMI-103 for phenylketonuria (PKU) and the juMPStart Phase 1 gene therapy trial...
Dec 12, 2022 08:00 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of the Company’s long-term investors. Recently an amended securities fraud complaint was filed against Homology on...
Nov 10, 2022 04:07 pm ET
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments. “We remain on track to provide an update from our...
Oct 27, 2022 09:00 am ET
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1, open-label, dose-escalation study evaluating one-time gene editing candidate HMI-103 in adults with...
Oct 06, 2022 08:30 am ET
Homology Medicines to Participate at Upcoming Conferences
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President...
Sep 27, 2022 08:15 am ET
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities...
Sep 16, 2022 08:00 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of the Company’s long-term investors. Recently an amended securities fraud complaint was filed against Homology on...
Sep 06, 2022 04:01 pm ET
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the promotion of Albert Seymour, Ph.D., to Chief Executive Officer (CEO), President and member of the Board of Directors. He is succeeding Arthur Tzianabos,...
Aug 15, 2022 04:10 pm ET
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the second quarter ended June 30, 2022, highlighted recent accomplishments, and provided a business update. “Homology has a strong cash...
Aug 11, 2022 04:05 pm ET
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the details of HMI-204, its optimized, in vivo, one-time gene therapy product candidate for the treatment of metachromatic leukodystrophy (MLD). Following a...
Jul 05, 2022 08:30 am ET
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of data showing that AAVHSC16, one of the capsids in its family of 15 naturally occurring AAVHSCs, demonstrated low levels of...
Jun 29, 2022 08:00 am ET
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB’s The Genome Engineering Conference: Cutting-Edge Research and Applications on June 29, 2022...
Jun 13, 2022 08:00 am ET
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) lifted the clinical hold previously placed on the pheNIX gene therapy clinical trial with investigational HMI-102...
Jun 06, 2022 11:56 am ET
Homology (FIXX) Alert: Johnson Fistel, Globally-Recognized Law Firm, encourages Long Term Shareholders to Contact the Firm for More Information
Johnson Fistel, LLP is investigating potential claims on behalf of Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) against certain of its officers and directors. Recently there was a class action filed against Homology. The...
May 24, 2022 01:44 pm ET
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX
NEW YORK, May 24, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the "Class Period"), seeking to recover da
May 24, 2022 10:54 am ET
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Homology Medicines, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, May 24, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Homology Medicines, Inc. ("Homology" or "the Company") (NASDAQ: FIXX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
May 24, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, May 24, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
May 23, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vertiv Holding Co. (NYSE: VRT), Homology Medicines, Inc. (NASDAQ: FIXX), Volta,...
May 23, 2022 11:00 am ET
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Homology Medicines, Inc. (FIXX) Shareholders of Class Action Last Few Hours to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX)
May 23, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, May 23, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
May 20, 2022 09:00 pm ET
HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the “Class Period”). Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
May 20, 2022 05:15 pm ET
FIXX FINAL DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead...
May 20, 2022 04:38 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys Before May 24th Deadline in Securities Class Action
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
May 20, 2022 05:45 am ET
FIXX SHAREHOLDER ALERT: Jakubowitz Law Reminds Homology Shareholders of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, May 20, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX).
May 19, 2022 01:59 pm ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 19, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
May 19, 2022 09:50 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vertiv Holding Co. (NYSE: VRT), Homology Medicines, Inc. (NASDAQ: FIXX), Volta,...
May 18, 2022 06:00 am ET
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, unveiled today the mechanism of action (MOA) and optimization of HMI-103, the nuclease-free gene editing candidate currently in a Phase 1 trial for phenylketonuria (PKU)....
May 18, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Homology Medicines, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, May 18, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc..
May 17, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, May 17, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
May 16, 2022 04:15 pm ET
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments. “During the first quarter of 2022, we took additional steps...
May 16, 2022 10:26 am ET
FAT, VRT & FIXX Class Actions Reminder: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors of Upcoming Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 16, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, May 16, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
May 13, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vertiv Holding Co. (NYSE: VRT), Homology Medicines, Inc. (NASDAQ: FIXX), Volta,...
May 13, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vertiv Holding Co. (NYSE: VRT), Homology Medicines, Inc. (NASDAQ: FIXX), Volta,...
May 13, 2022 05:45 am ET
FIXX SHAREHOLDER ALERT: Jakubowitz Law Reminds Homology Shareholders of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, May 13, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX).
May 12, 2022 07:40 pm ET
HOMOLOGY MEDICINES, INC. Investors: Contact the Portnoy Law Firm to Recover Losses
The Portnoy Law Firm advises Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) investors that a class action filed on behalf of investors. Homology Medicine investors that lost money on their investment are encouraged to contact...
May 12, 2022 05:45 am ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 12, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
May 11, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Homology Medicines, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, May 11, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc..
May 10, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, May 10, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
May 10, 2022 01:35 am ET
HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Ag
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
May 09, 2022 05:20 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important May 24 Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead...
May 09, 2022 12:44 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, May 24th Deadline Approaching in Securities Class Action
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
May 09, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, May 9, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
May 08, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FAT, Cano, Vertiv, and Homology and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FAT Brands, Inc. (NASDAQ: FAT), Cano Health, Inc. (NYSE: CANO), Vertiv Holding...
May 06, 2022 05:38 pm ET
FIXX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
SAN DIEGO, May 6, 2022 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, inclusive ("Class Period") have until May 24, 2022 to seek appointment as lead plaintiff in Pizzuto v. Homology Medicines, Inc., No. 22-cv-01968 (C.D. Cal.).   
May 06, 2022 05:45 am ET
FIXX SHAREHOLDER ALERT: Jakubowitz Law Reminds Homology Shareholders of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, May 6, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX).
May 05, 2022 10:45 am ET
FAT, VRT & FIXX Class Actions Reminder: Bronstein, Gewirtz & Grossman, LLC, A Recognized Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 05, 2022 05:45 am ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 5, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
May 04, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Homology Medicines, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, May 4, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc..
May 03, 2022 06:16 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead...
May 03, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, May 3, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
May 03, 2022 12:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX
NEW YORK, May 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the "Class Period"), seeking to recover damag
May 02, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FAT, Cano, Vertiv, and Homology and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FAT Brands, Inc. (NASDAQ: FAT), Cano Health, Inc. (NYSE: CANO), Vertiv Holding...
May 02, 2022 04:56 pm ET
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the first presentation detailing the optimization and mechanism of action of its HMI-103 nuclease-free gene editing candidate for phenylketonuria (PKU) will...
May 02, 2022 04:34 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
May 02, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
Apr 29, 2022 05:45 am ET
FIXX SHAREHOLDER ALERT: Jakubowitz Law Reminds Homology Shareholders of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 29, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX).
Apr 28, 2022 01:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX
Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) and certain of its officers.   The class action, filed in the United States District Court for the...
Apr 28, 2022 05:45 am ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 28, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
Apr 28, 2022 12:30 am ET
HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Ag
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 27, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vertiv Holding Co. (NYSE: VRT), Homology Medicines, Inc. (NASDAQ: FIXX), Volta,...
Apr 27, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Homology Medicines, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, April 27, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc.
Apr 26, 2022 11:24 am ET
FIXX NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022...
Apr 26, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, April 26, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
Apr 25, 2022 04:34 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
Apr 25, 2022 12:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX
NEW YORK, April 25, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the "Class Period"), seeking to recover da
Apr 25, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 25, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
Apr 22, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FAT, Cano, Vertiv, and Homology and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FAT Brands, Inc. (NASDAQ: FAT), Cano Health, Inc. (NYSE: CANO), Vertiv Holding...
Apr 22, 2022 03:10 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead...
Apr 21, 2022 08:30 am ET
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., Chief Scientific Officer, has been promoted to President of Homology. In addition to his role as CSO, Dr. Seymour will assume broader...
Apr 21, 2022 05:45 am ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 21, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
Apr 20, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Homology Medicines, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, April 20, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc..
Apr 19, 2022 07:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX
Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) and certain of its officers.   The class action, filed in the United States District Court for the...
Apr 19, 2022 10:41 am ET
FAT, VRT & FIXX Class Actions Reminder: Bronstein, Gewirtz & Grossman, LLC, A Recognized Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 19, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, April 19, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
Apr 18, 2022 09:24 am ET
FIXX FRAUD: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
Apr 18, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 18, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
Apr 17, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FAT, Cano, Vertiv, and Homology and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FAT Brands, Inc. (NASDAQ: FAT), Cano Health, Inc. (NYSE: CANO), Vertiv Holding...
Apr 16, 2022 06:00 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022...
Apr 15, 2022 10:56 am ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX
Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the...
Apr 15, 2022 05:45 am ET
FIXX SHAREHOLDER ALERT: Jakubowitz Law Reminds Homology Shareholders of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 15, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX).
Apr 14, 2022 06:14 pm ET
FIXX Stock Alert: Robbins LLP Reminds Investors of Class Action Against Homology Medicines, Inc. (FIXX)
The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10,...
Apr 14, 2022 05:45 am ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
Apr 13, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders Of Homology Medicines, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, April 13, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc..
Apr 12, 2022 03:05 pm ET
FIXX Stock News: Robbins LLP Investigates Homology Medicines, Inc. (FIXX) for Shareholders
Shareholder rights law firm Robbins LLP is investigating Homology Sciences, Inc. (NASDAQ: FIXX) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws in relation to the misstatements concerning its lead drug candidate HMI-102. Homology is a genetic medicines company
Apr 12, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, April 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
Apr 11, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Homology and Lucid and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Homology Medicines, Inc. (NASDAQ: FIXX) and Lucid Group, Inc. (NASDAQ: LCID)....
Apr 11, 2022 06:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the "Class Period"), seeking to recover da
Apr 11, 2022 03:37 pm ET
FIXX CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
Apr 11, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 11, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
Apr 08, 2022 06:15 pm ET
FIXX LOSS ALERT: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022...
Apr 08, 2022 05:45 am ET
FIXX SHAREHOLDER ALERT: Jakubowitz Law Reminds Homology Shareholders of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX).
Apr 07, 2022 01:20 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX
Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the...
Apr 07, 2022 06:15 am ET
HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Ag
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 07, 2022 05:45 am ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 7, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
Apr 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Embark, Homology, and Lucid and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Embark Technology, Inc. (NASDAQ: EMBK), Homology Medicines, Inc. (NASDAQ: FIXX)...
Apr 06, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders Of Homology Medicines, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, April 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc..
Apr 05, 2022 09:00 pm ET
HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the “Class Period”). Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Apr 05, 2022 06:05 am ET
HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Ag
Did you lose money on investments in Homology Medicines?  If so, please visit Homology Medicines, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.                                                                                       
Apr 05, 2022 05:45 am ET
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders
NEW YORK, April 5, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) alleging that the Company violated federal securities laws.
Apr 04, 2022 03:26 pm ET
FIXX ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
Apr 04, 2022 10:25 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Homology Medicines, Inc. (FIXX) Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers, on behalf of all...
Apr 04, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Homology Investors of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 4, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
Apr 03, 2022 04:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the "Class Period"), seeking to recover dam
Apr 02, 2022 06:05 pm ET
FIXX DEADLINE: Investors with Substantial Losses Have Opportunity to Lead Homology Medicines, Inc. Class Action Lawsuit
SAN DIEGO , April 2, 2022 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, inclusive (the "Class Period") have until May 24, 2022 to seek appointment as lead plaintiff in Pizzuto v. Homology Medicines, Inc., No. 22-cv-01968 (C.D. Cal.).  Commenced on March 25, 2022, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934. 
Apr 02, 2022 12:24 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead plaintiff deadline.
Apr 01, 2022 09:00 pm ET
HOMOLOGY ALERT: Bragar Eagel & Squire, P.C. is Investigating Homology Medicines, Inc. on Behalf of Homology Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of Homology stockholders. Our investigation concerns whether Homology has violated the federal securities laws and/or engaged in other unlawful business practices.
Apr 01, 2022 07:31 pm ET
FIXX ALERT: Investors with Substantial Losses Have Opportunity to Lead Homology Medicines, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”) have until May 24, 2022 to seek appointment as lead plaintiff in Pizzuto v. Homology Med
Apr 01, 2022 05:45 am ET
FIXX SHAREHOLDER ALERT: Jakubowitz Law Reminds Homology Shareholders of a Lead Plaintiff Deadline of May 24, 2022
NEW YORK, April 1, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX).
Mar 31, 2022 05:15 pm ET
ROSEN, A LONGSTANDING LAW FIRM, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the...
Mar 31, 2022 04:17 pm ET
HOMOLOGY MEDICINES, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Centr
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Central District of California against Homology Medicines, Inc. ("Homology" or the...
Mar 31, 2022 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Homology Medicines, Inc. (FIXX) Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX)
Mar 31, 2022 07:05 am ET
HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Ag
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Mar 31, 2022 05:45 am ET
FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 31, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
Mar 31, 2022 12:04 am ET
ALERT: Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FIXX
SAN DIEGO, March 31, 2022 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, inclusive (the "Class Period") have until May 24, 2022 to seek appointment as lead plaintiff in Pizzuto v. Homology Medicines, Inc., No. 22-cv-01968 (C.D. Cal.).  Commenced on March 25, 2022, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934. 
Mar 30, 2022 07:36 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX
Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) and certain of its officers. The class action, filed in the United States District Court for the...
Mar 30, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Homology Medicines, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 24, 2022 - (NASDAQ: FIXX)
NEW YORK, March 30, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Homology Medicines, Inc..
Mar 29, 2022 08:28 pm ET
FIXX Shareholder Class Action: Robbins LLP Reminds Investors of Class Action Against Homology Medicines, Inc. (FIXX)
The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, for violations of the Securities Exchange Act of
Mar 29, 2022 05:08 pm ET
EQUITY NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Homology Medicines, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 24, 2022.
Mar 29, 2022 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Homology Medicines, Inc. (FIXX) Shareholders of Class Action and Encourages Investors to Contact the Firm
NEW YORK, March 29, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/fixx.
Mar 29, 2022 10:00 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Homology Medicines, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Homology Medicines, Inc. (“Homology” or “the Company”) (NASDAQ:
Mar 29, 2022 09:31 am ET
FIXX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed
SAN FRANCISCO, March 29, 2022 /PRNewswire/ -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now.
Mar 29, 2022 05:25 am ET
(FIXX) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Homology Holdings Class Action Lawsuit
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Homology Medicines, Inc. (NASDAQ: FIXX). The class action is on behalf of shareholders who purchased Homology securities...
Mar 28, 2022 07:57 pm ET
ALERT: Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FIXX
Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”) have until May 24, 2022 to seek appointment as lead plaintiff in Pizzuto v. Homology Med
Mar 28, 2022 05:31 pm ET
SHAREHOLDER ALERT: Robbins LLP Informs Shareholders of Class Action Against Homology Medicines, Inc. (FIXX)
The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, for violations of the Securities Exchange Act of
Mar 28, 2022 05:25 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed
Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now.   A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead...
Mar 28, 2022 04:10 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. (FIXX)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) in the United States District Court for the Central District of California on behalf of...
Mar 28, 2022 02:10 pm ET
HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. (NASDAQ:
Did you lose money on investments in Homology Medicines?  If so, please visit Homology Medicines, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.                                                                                     
Mar 28, 2022 12:59 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Homology Medicines, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Homology Medicines, Inc. (“Homology” or “the Company”) (NASDAQ:
Mar 25, 2022 09:42 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Homology Medicines, Inc., and Certain Officers - FIXX
NEW YORK, March 25, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the "Class Period"), seeking to recover
Mar 23, 2022 04:10 pm ET
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2021, and highlighted recent accomplishments. “We recently closed our deal with Oxford...
Mar 16, 2022 08:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX
NEW YORK, March 16, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 12, 2022 04:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX
Pomerantz LLP is investigating claims on behalf of investors of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Mar 10, 2022 04:01 pm ET
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the successful closing of the deal with Oxford Biomedica plc (LSE: OXB) to establish an Adeno-Associated Virus (AAV) Manufacturing and Innovation Business. The...
Mar 04, 2022 09:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX
Pomerantz LLP is investigating claims on behalf of investors of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Mar 03, 2022 07:30 am ET
Homology Medicines to Participate in Upcoming Investor Conferences
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences: Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion – Gene Editing: March 8 at...
Mar 01, 2022 02:35 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX
NEW YORK, March 1, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Feb 18, 2022 04:05 pm ET
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has...
Feb 10, 2022 11:40 am ET
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WOR
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today multiple presentations on HMI-203 gene therapy candidate for the treatment of Hunter syndrome (MPS II), which is being evaluated in juMPStart, a Phase 1...
Jan 28, 2022 02:30 am ET
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. wit
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company, announced today that the companies have agreed to...
Nov 15, 2021 07:10 am ET
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2021, and highlighted recent accomplishments. “We realized our goal to have three clinical programs...
Nov 03, 2021 08:28 am ET
Homology Medicines to Participate in Upcoming Investor Conferences
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in the following virtual conferences: Credit Suisse 30th Annual Healthcare Conference: Company presentation on November 8 at 10:30...
Oct 21, 2021 07:00 am ET
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinical data spanning its clinical-stage gene therapy program for mucopolysaccharidosis type II (MPS II, or Hunter syndrome),...
Oct 20, 2021 08:30 am ET
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations of nonclinical data and patient and caregiver feedback that support the Company’s clinical programs for mucopolysaccharidosis type II (MPS II), or...
Oct 18, 2021 08:30 am ET
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has initiated the Phase 1 trial for HMI-203, a one-time, in vivo gene therapy candidate for the treatment of adults with mucopolysaccharidosis type II...
Oct 12, 2021 04:05 pm ET
Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the pheEDIT Phase 1 clinical trial for HMI-103, a one-time, in vivo product candidate that utilizes a gene editing approach for phenylketonuria (PKU), based on...
Aug 12, 2021 04:05 pm ET
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today financial results for the second quarter ended June 30, 2021, and highlighted recent accomplishments. “We continue to demonstrate the breadth and...
Aug 05, 2021 08:30 am ET
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company’s Scientific Advisory Board, on which she has served since...
Aug 04, 2021 08:30 am ET
Homology Medicines to Participate in Upcoming Investor Conferences
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences: BTIG Virtual Biotechnology Conference: August 9 at 1:30 p.m. ETCanaccord...
May 13, 2021 07:00 am ET
Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of data in multiple disease areas supporting the Company’s human hematopoietic stem cell-derived adeno-associated virus vector (AAVHSC) platform....
May 06, 2021 04:05 pm ET
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today financial results for the first quarter ended March 31, 2021, and highlighted recent accomplishments. “We are in the midst of a...
May 03, 2021 08:00 am ET
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today new preclinical data that demonstrated in vivo nuclease-free gene editing of retinal cells at the virtual Association for Research in Vision and...
Apr 28, 2021 08:00 am ET
Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today a new approach to its AAVHSC platform that delivers one-time gene therapy to produce antibodies throughout the body. Preclinical data that...
Apr 14, 2021 08:30 am ET
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today two presentations highlighting clinical and preclinical data from the Company’s phenylketonuria (PKU) and MPS II (Hunter syndrome) in vivo gene...
Apr 12, 2021 08:30 am ET
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Tim Kelly has been promoted to Chief Operating Officer, effective immediately. Previously, Mr. Kelly held the role of Chief Technical Operations Officer and...
Apr 07, 2021 08:52 am ET
Homology Medicines Announces Pricing of Public Offering of Common Stock
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for proceeds of approximately $50.0 million, before deducting estimated offering expenses payable by...
Apr 06, 2021 04:19 pm ET
Homology Medicines Announces Proposed Public Offering of Common Stock
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public...
Mar 11, 2021 04:10 pm ET
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2020, and highlighted recent accomplishments. “In 2020, we remained...
Mar 01, 2021 07:30 am ET
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today it has regained worldwide exclusive rights from Novartis to research, develop, manufacture and commercialize Homology’s proprietary nuclease-free...
Feb 25, 2021 08:00 am ET
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences: Cowen 41st Annual Health Care Conference Panel discussion: March 1 at 11:40 a.m. ET H.C....
Feb 08, 2021 02:50 pm ET
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today the first scientific presentation of data from IND-enabling studies with its HMI-203 gene therapy development candidate for Hunter syndrome (MPS...
Jan 06, 2021 08:00 am ET
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today plans to progress its gene therapy and gene editing platform, and unveiled plans to have three clinical programs and a development candidate in a new therapeutic...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.